

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) Medicament to counteract the loss of cellular differentiation in tumour and non tumour pathologies characterised in that it comprises as active principle an effective amount of at least one inhibitor compound of Reverse Transcriptase (RT) said compound being able to bind the hydrophobic pocket on the RT subunit p66.
2. (original) Medicament according to claim 1 wherein the tumour pathologies are selected in the group of leukaemia and solid tumours such as epithelial tumors, mesenchymal tumors, tumors of the nervous system, iteratocarcinomas, fibro- and osteo-sarcomas, colon carcinoma, breast carcinoma, glioma and hepatoma.
3. (previously presented) Method to counteract the loss of cellular differentiation in tumour and non tumour pathologies comprising the step of administering to a subject in need an effective amount of at least one inhibitor compound of Reverse Transcriptase.
4. (previously presented) The method according to claim 3 wherein the compound reconverts the differentiated cells into phenotypically normal cells.
5. (previously presented) The method according to claim 3 wherein the tumour pathologies are selected from the group of leukaemia and solid tumours such as epithelial tumors, mesenchymal tumors, tumors of the nervous system, teratocarcinomas, fibro- and osteo-sarcomas, colon carcinoma, breast carcinoma, glioma and hepatoma.
6. (previously presented) The method according to claim 3 wherein the compound is selected from the 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine class of compounds.
7. (previously presented) The method according to claim 3 wherein the compound is selected from the group of: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.

8. (previously presented) The method according to claim 3 wherein the pharmaceutical compositions further comprise carriers and/or diluents and/or solvents and/or excipients for the preparation of compositions for oral, intravenous, intramuscular or hypodermic injection administration.

9. (currently amended) The method according to any one of claims 3-8 wherein the pharmaceutical compositions are in the form of pills, suspensions or solutions.

10. (previously presented) Method to treat cell proliferation in tumour and non tumour pathologies comprising the step of administering to a subject in need an effective amount of a compound of the 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines.

11. (previously presented) Method to treat cell proliferation in tumour and non tumour pathologies comprising the step of administering to a subject in need an effective amount of at least one compound selected from the group of: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.